行情

CLVS

CLVS

Clovis肿瘤药物
NASDAQ

实时行情|Nasdaq Last Sale

5.84
+0.06
+1.04%
盘后: 5.90 +0.06 +1.03% 17:59 06/14 EDT
开盘
5.90
昨收
5.78
最高
6.25
最低
5.80
成交量
961.74万
成交额
--
52周最高
11.10
52周最低
4.080
市值
6.11亿
市盈率(TTM)
-1.5799
分时
5日
1月
3月
1年
5年
Clovis Oncology 股价走高;交易商传阅 Aetna 文件,显示在 BCRA 突变前列腺癌中添加了 Co 的 RUBRACA 到承保名单
https://www.aetna.com/products/rxnonmedicare/data/2021/Destination/Rubraca_2256-A_SGM_P2020.html
Benzinga · 8小时前
午后市场更新:道指跌逾 50 点; Comtech Telecommunications 股价暴跌
Toward the end of trading Wednesday, the Dow traded down 0.16% to 34,545.82 while the NASDAQ rose 0.26% to 13,960.49. The S&P also rose, gaining 0.07% to 4,230.24.
Benzinga · 5天前
Benzinga Pro 2021 年 6 月 9 日星期三最值得关注的 5 只股票:EA、WISH、SCYX、COIN、CLVS
Today's 5 Stock Ideas Electronic Arts (EA) - A play on the upcoming video game conference, E3. The event runs from Jun. 12 to Jun. 15. Benzinga will be hosting a preview of E3 on its YouTube
Benzinga · 5天前
28 只股票在周三的盘前交易时段内波动
Gainers Aethlon Medical, Inc. (NASDAQ: AEMD) rose 72.4% to $3.81 in pre-market trading following Zacks article 'AEMD: First Ever In Vivo Removal Of COVID Virus From Bloodstream Of An Infected Patient.'
Benzinga · 5天前
克洛维斯肿瘤学股票能否为下一步行动做准备?
Clovis Oncology Inc. (NASDAQ: CLVS) is gearing up to present this week at the American Society of Clinical Oncology annual meeting, which runs June 4-8. The company is expected to report updated Phase 1b results on Lucitanib and Opdivo in patients with adv...
Benzinga · 06/03 18:40
生物技术的一周提前:ASCO演示文稿的前场和中心,FDA对Scynexis,Liminal和Alkermes做出的决定
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-specific news flow dictated stock moves during the week.
Benzinga · 05/31 15:06
为什么Clovis肿瘤学股票今天的交易价格较低
Clovis Oncology (NASDAQ: CLVS) shares are trading lower after the company announced a $75 million at-the-market equity offering program.
Benzinga · 05/18 15:23
生物技术日报:Spero获得NIAID资助,葛兰素史克发布COVID-19数据,BioNTech获得新的CFO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 17)
Benzinga · 05/18 11:44
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解CLVS最新的财务预测,通过CLVS每股收益,每股净资产,每股现金流等数据分析Clovis肿瘤药物近期的经营情况,然后做出明智的投资选择。
分析师评级

6位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测CLVS价格均价为6.35,最高价位12.00,最低价为3.000。
EPS
机构持股
总机构数: 281
机构持股: 5,823.17万
持股比例: 55.69%
总股本: 1.05亿
类型机构数股数
增持
44
623.79万
建仓
40
145.66万
减持
43
789.40万
平仓
31
483.10万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.10%
制药与医学研究
+0.13%
高管信息
Non-Executive Chairman/Independent Director
Ginger Graham
President/Chief Executive Officer/Co-Founder/Director
Patrick Mahaffy
Co-Founder/Executive Vice President
Gillian Ivers-Read
Co-Founder/Executive Vice President
Gillian Ivers - Read
Chief Financial Officer/Executive Vice President
Daniel Muehl
Executive Vice President/Chief Scientific Officer
Thomas Harding
Senior Vice President
C. Dale Hooks
Executive Vice President/General Counsel
Paul Gross
Executive Vice President/Director of Human Resources
Ann Bozeman
Executive Vice President
Lindsey Rolfe
Independent Director
Brian Atwood
Independent Director
Robert Azelby
Independent Director
James Blair
Independent Director
Richard Fair
Independent Director
Keith Flaherty
Independent Director
Paul Klingenstein
Independent Director
Edward McKinley
Independent Director
Edward Mckinley
Independent Director
Thorlef Spickschen
暂无数据
CLVS 简况
Clovis Oncology, Inc.是一家生物制药公司,专注于在美国、欧洲和其他国际市场获得、开发和商业化抗癌药剂。该公司的产品Rubraca(rucaparib)是一种多聚腺苷二磷酸(ADP)-核糖聚合酶(PARP)的口服小分子抑制剂,在美国上市销售,用于复发上皮性卵巢癌和输卵管癌或原发性腹膜癌两种适应症。该公司还提供Lucitanib,它是一种口服的、研究性的以及有效的血管内皮生长因子受体1-3(VEGFR1-3)、血小板生长因子受体α和β以及成纤维细胞生长因子受体1-3(FGFR1-3)的酪氨酸激酶活性抑制剂。

微牛提供Clovis Oncology Inc(NASDAQ-CLVS)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CLVS股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CLVS股票基本功能。